{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:00:02Z","timestamp":1791568802150,"version":"4.3.4"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T00:00:00Z","timestamp":1598313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2020.00868","type":"journal-article","created":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T06:31:58Z","timestamp":1598337118000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":29,"title":["Reappraisal of Oral Steroid Therapy for Myasthenia Gravis"],"prefix":"10.3389","volume":"11","author":[{"given":"Tomihiro","family":"Imai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Nagane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyuki","family":"Uzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Murai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiaki","family":"Utsugisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/S0022-510X(97)05370-7","article-title":"Randomized trial of azathioprine or prednisone for initial immunosuppressive treatment of myasthenia gravis","volume":"150","author":"Bromberg","year":"1997","journal-title":"J Neurol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1136\/jnnp.56.11.1157","article-title":"A randomised clinical trial comparing prednisone and azathioprine in myasthenia gravis. Results of a second interim analysis","volume":"56","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1749-6632.1993.tb22937.x","article-title":"A clinical therapeutic trial of cyclosporine in myasthenia gravis","volume":"681","author":"Tindall","year":"1993","journal-title":"Ann N Y Acad Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis","volume":"71","year":"2008","journal-title":"Neurology"},{"key":"B6","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/mus.21462","article-title":"Factors associated with response to calcineurin inhibitors in myasthenia gravis","volume":"41","author":"Nagane","year":"2010","journal-title":"Muscle Nerve"},{"key":"B7","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/1471-2377-11-97","article-title":"A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis","volume":"11","author":"Heckmann","year":"2011","journal-title":"BMC Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1136\/thx.50.10.1080","article-title":"Comparative effects of plasma exchange and pyridostigmine on respiratory muscle strength and breathing pattern in patients with my- asthenia gravis","volume":"50","author":"Goti","year":"1995","journal-title":"Thorax"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11748-005-1001-y","article-title":"Beneficial effects of plasmapheresis before thymectomy on the outcome in myasthenia gravis","volume":"53","author":"Nagayasu","year":"2005","journal-title":"Jpn J Thorac Cardiovasc Surg."},{"key":"B11","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1212\/01.wnl.0000256698.69121.45","article-title":"IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial","volume":"68","author":"Zinman","year":"2007","journal-title":"Neurology"},{"key":"B12","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high dose immunoglobulin in myasthenia gravis","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1046\/j.1525-1594.2001.06717.x","article-title":"Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis","volume":"25","author":"Ronager","year":"2001","journal-title":"Artif Organs"},{"key":"B14","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis. Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1212\/WNL.0000000000002795","article-title":"A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis","volume":"87","author":"Pasnoor","year":"2016","journal-title":"Neurology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1212\/WNL.50.6.1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group","volume":"50","author":"Palace","year":"1998","journal-title":"Neurology"},{"key":"B17","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1212\/01.wnl.0000312374.95186.cc","article-title":"An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis","volume":"71","author":"Sanders","year":"2008","journal-title":"Neurology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1002\/mus.21640","article-title":"Mycophenolate mofetil in AChR-antibody-positive myasthenia gravis: outcomes in 102 patients","volume":"41","author":"Hehir","year":"2010","journal-title":"Muscle Nerve"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1001\/jama.1935.02760230013004","article-title":"Myasthenia gravis: effect of treatment with anterior pituitary extract","volume":"104","author":"Simon","year":"1935","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime course of myasthenia gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"B21","first-page":"845","article-title":"Adrenocorticotropic hormone, adrenal steroids, and the adrenal cortex","volume-title":"Goodman & Gilman's: The Pharmacological Basis of Therapeutics.","author":"Schimmer","year":"2018"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/S0140-6736(70)90392-2","article-title":"Alternate-day prednisone in a patient with myasthenia gravis","volume":"2","author":"Warmolts","year":"1970","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann Neurol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1212\/WNL.34.2.170","article-title":"Myasthenia gravis: prolonged treatment with steroids","volume":"34","author":"Sghirlanzoni","year":"1984","journal-title":"Neurology."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.jocn.2005.12.041","article-title":"Clinical predictors of steroid-induced exacerbation in myasthenia gravis","volume":"13","author":"Bae","year":"2006","journal-title":"J Clin Neurosci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"CD002828","DOI":"10.1002\/14651858.CD002828.pub2","article-title":"Corticosteroids for myasthenia gravis","volume":"2","author":"Schneider-Gold","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"B27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/cen3.12180","article-title":"Japanese clinical guidelines for myasthenia gravis: putting into practice","volume":"6","author":"Murai","year":"2015","journal-title":"Clin Exp Neuroimmunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1159\/000236781","article-title":"Glucocorticoid-induced apoptosis of lymphoid cells","volume":"105","author":"Schwartzman","year":"1994","journal-title":"Int Arch Allergy Immunol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1056\/NEJM199505183322008","article-title":"The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation","volume":"332","author":"Chrousos","year":"1995","journal-title":"N Eng J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1172\/JCI110408","article-title":"Immunoglobulin production induced in vitro by glucocorticoid hormones: T cell-dependent stimulation of immunoglobulin production without B cell proliferation in cultures of human peripheral lymphocytes","volume":"68","author":"Grayson","year":"1981","journal-title":"Clin Invest"},{"key":"B31","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1126\/science.152.3723.782","article-title":"Steroids and serum complement in mice: influence of hydrocortisone, diethylstilbestrol, and testosterone","volume":"152","author":"Caren","year":"1966","journal-title":"Science"},{"key":"B32","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/mus.24438","article-title":"Oral corticosteroid therapy and present disease status in myasthenia gravis","volume":"51","author":"Imai","year":"2015","journal-title":"Muscle Nerve"},{"key":"B33","first-page":"375","article-title":"Corticosteroids: a review with emphasis on complications of prolonged systemic therapy","volume":"62","author":"Truhan","year":"1989","journal-title":"Ann Allergy"},{"key":"B34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3109\/10673229809000307","article-title":"Mood symptoms during corticosteroid therapy: a review","volume":"5","author":"Brown","year":"1998","journal-title":"Harvard Rev Psychiatry."},{"key":"B35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jns.2003.09.016","article-title":"Treatment and outcome of myasthenia gravis: retrospective multi-center analysis of 470 Japanese patients, 1999\u20132000","volume":"224","author":"Kawaguchi","year":"2004","journal-title":"J Neurol Sci"},{"key":"B36","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1136\/jnnp.2004.042176","article-title":"Long-term treatment of generalised myasthenia gravis with FK506 (tacrolimus)","volume":"76","author":"Konishi","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B37","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000085833","article-title":"Efficacy of low-dose FK506 in the treatment of myasthenia gravis - a randomized pilot study","volume":"53","author":"Nagane","year":"2005","journal-title":"Eur Neurol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/j.1468-1331.2008.02130.x","article-title":"Monitoring treatment with cyclosporine microemulsion in myasthenia gravis","volume":"15","author":"Utsugisawa","year":"2008","journal-title":"Eur J Neurol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.7164\/antibiotics.40.1256","article-title":"FK506, a novel immunosuppressant isolated from a streptomyces. II. Immunosuppressive effect of FK506 in vitro","volume":"40","author":"Kino","year":"1987","journal-title":"J Antibiot"},{"key":"B40","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/0167-5699(92)90111-J","article-title":"The mechanism of action of cyclosporin A and FK506","volume":"13","author":"Schreiber","year":"1992","journal-title":"Immunol Today"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.2165\/00003495-200161130-00006","article-title":"Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral\u00ae) in organ transplantation","volume":"61","author":"Dunn","year":"2001","journal-title":"Drugs"},{"key":"B42","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1056\/NEJM198703193161205","article-title":"Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis","volume":"316","author":"Tindall","year":"1987","journal-title":"N Engl J Med"},{"key":"B43","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1007\/s004150050141","article-title":"Long-term cyclosporine treatment in a group of severe myasthenia gravis patients","volume":"244","author":"Bonifati","year":"1997","journal-title":"J Neurol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1212\/WNL.55.3.448","article-title":"Retrospective analysis of the use of cyclosporine in myasthenia gravis","volume":"55","author":"Ciafaloni","year":"2000","journal-title":"Neurology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1002\/mus.10018","article-title":"Successful treatment of myasthenia gravis with tacrolimus","volume":"25","author":"Evoli","year":"2002","journal-title":"Muscle Nerve."},{"key":"B46","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1600-0404.2005.00378.x","article-title":"Cyclosporine in the treatment of myasthenia gravis","volume":"111","author":"Lavrnic","year":"2005","journal-title":"Acta Neurol Scand"},{"key":"B47","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1136\/jnnp-2017-316625","article-title":"Oral corticosteroid dosing regimen and long-term prognosis in generalized myasthenia gravis: a multicenter cross-sectional study in Japan","volume":"89","author":"Imai","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B48","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1002\/mus.23398","article-title":"The MG-QOL15 Japanese version: validation and associations with clinical factors","volume":"46","author":"Masuda","year":"2012","journal-title":"Muscle Nerve"},{"key":"B49","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.pharmthera.2011.12.004","article-title":"Maps and legends: the quest for dissociated ligands of the glucocorticoid receptor","volume":"134","author":"Clark","year":"2012","journal-title":"Pharmacol Ther"},{"key":"B50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.rdc.2015.08.002","article-title":"Corticosteroids-mechanisms of action in health and disease","volume":"42","author":"Ramamoorthy","year":"2016","journal-title":"Rheum Dis Clin North Am"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00868\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,25]],"date-time":"2020-08-25T06:32:00Z","timestamp":1598337120000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fneur.2020.00868\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,25]]},"references-count":50,"alternative-id":["10.3389\/fneur.2020.00868"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2020.00868","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,25]]},"article-number":"868"}}